This product was innovative years ago when it came out: biomaterial, non-invasive, and easy to administer. It is temporary b/c the collagen is absorbed and you need to get repeated injections. Bard thought the re-occuring revenue would be a windfall, patients thought otherwise. So... they bought a start up years ago (1997) which would be a permanent solution. They did nothing with it. Why? That is what I want to know? As for a new supplier of collagen, yes very possible.
Thank you for replying. The 1997 product was Tegress but it turned out to be not easy to inject so is not promoted anymore. Through contact I have in Europe, I might be able to auggest a new bulking agent to BCR, but only if the US market is big enough. Do you think Contigen is < $20 M, $20 to 40 M or >$40 M? Would appreciate a POV as hard to peel away the onion of BCR's urology division